StartsideABBV34 • BVMF
add
Abbvie Inc BDR
Forrige sluttkurs
62,90 R$
Dagsintervall
62,90 R$ - 63,90 R$
Årsintervall
54,36 R$ - 79,10 R$
Markedsverdi
322,03 mrd. USD
Gjennomsnittlig volum
5,63k
I nyhetene
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
| (USD) | mars 2025info | Endring år til år |
|---|---|---|
Omsetning | 13,34 mrd. | 8,39 % |
Driftskostnader | 5,28 mrd. | 8,44 % |
Nettoomsetning | 1,29 mrd. | −6,06 % |
Netto resultatmargin | 9,64 | −13,31 % |
Fortjeneste per aksje | 2,46 | 6,49 % |
EBITDA | 6,10 mrd. | 11,89 % |
Faktisk avgiftssats | 22,40 % | — |
Balanseregnskap
Totale aktiva
Totale passiva
| (USD) | mars 2025info | Endring år til år |
|---|---|---|
Kontant / kortsiktige inv. | 5,18 mrd. | −71,35 % |
Totale aktiva | 136,16 mrd. | −8,54 % |
Totale passiva | 134,70 mrd. | −4,35 % |
Total egenkapital | 1,46 mrd. | — |
Utestående aksjer | 1,77 mrd. | — |
P/B-forhold | 78,62 | — |
Avkastning på aktiva | 7,48 % | — |
Avkastning på kapital | 14,21 % | — |
Kontantstrøm
Netto kontantstrøm
| (USD) | mars 2025info | Endring år til år |
|---|---|---|
Nettoomsetning | 1,29 mrd. | −6,06 % |
Kontantstrøm fra drift | 1,64 mrd. | −59,53 % |
Kontanter fra investering | −735,00 mill. | 92,33 % |
Kontanter fra finansiering | −1,26 mrd. | −111,63 % |
Netto kontantstrøm | −349,00 mill. | −106,64 % |
Fri kontantstrøm | 1,12 mrd. | −73,12 % |
Om
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. Its major products are: Humira, approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis and administered via injection; Skyrizi, an interleukin-23 inhibitor also used to treat autoimmune diseases; Rinvoq, used to treat arthritis; and Botox. Its other major products include Imbruvica to treat cancer, Vraylar to treat schizophrenia and bipolar disorder, Venclexta to treat leukemia and lymphoma, Mavyret to treat Hepatitis C, and Epkinly, a blood-cancer therapy developed in partnership with Genmab. The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis. The company's pipeline also includes drug candidates for Parkinson's disease including Vyalev and tavapadon.
The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. Wikipedia
Grunnlagt
10. apr. 2012
Hovedkvarter
Nettsted
Ansatte
55 000
